Octreotide Ratiopharm (Octreotide Acetate)

Octreotide acetate mimics natural somatostatin and binds to somatostatin receptors, mainly sst2 and sst5. This binding blocks intracellular signalling pathways that normally stimulate the release of several hormones, thereby decreasing secretion of growth hormone, serotonin, vasoactive intestinal peptide and other peptides.

The specific dose and dosing schedule of Octreotide Ratiopham are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal hormone control while monitoring safety.

Safety data for octreotide acetate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Octreotide Ratiopham, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Octreotide Ratiopham is chemically identical to other octreotide products and shares the same mechanism of action. Differences may lie in formulation, packaging, and regulatory status. Clinicians choose a specific product based on factors such as availability, approved indications, and institutional preferences.

Octreotide Ratiopham should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution, which could affect product stability.

Octreotide Ratiopham is supplied as a sterile solution for injection. It can be given by intramuscular or intravenous injection, typically by a trained healthcare professional in a clinical setting, following the dosing instructions provided by the prescriber.

Serious adverse events, although uncommon, include pancreatitis, severe hypoglycaemia, gallbladder disease such as cholecystitis or gallstones, and anaphylactic reactions. Patients should be monitored for these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Octreotide Ratiopham is contraindicated in patients with known hypersensitivity to octreotide acetate or any of the formulation excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease, and it should be avoided in pregnant or nursing women unless clearly indicated.